4- (2,5- difluorophenyl)- N- (3- fluoro- 1- methylpiperidin- 4- yl)- 2- (hydroxymethyl)- N- methyl- 2- phenyl- 2,5- dihydro- 1H- pyrrole- 1- carboxamide
a kinesin spindle protein inhibitor and antineoplastic agent; structure in first source
Also Known As:
MK 0731; MK-0731; MK731 cpd
Networked: 2
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Agrawal, Nancy:
1 article
(06/2012)
|
| 2. | Chen, Cong:
1 article
(06/2012)
|
| 3. | DiPaola, Robert:
1 article
(06/2012)
|
| 4. | Holen, Kyle:
1 article
(06/2012)
|
| 5. | Hsu, Karl:
1 article
(06/2012)
|
| 6. | Liu, Glenn:
1 article
(06/2012)
|
| 7. | Rosenberg, Elizabeth:
1 article
(06/2012)
|
| 8. | Stein, Mark:
1 article
(06/2012)
|
| 9. | Tan, Antoinette R:
1 article
(06/2012)
|
| 10. | Wilding, George:
1 article
(06/2012)
|
Related Diseases
| 1. | Neoplasms (Cancer)
06/01/2012
- " This phase I trial examined safety, tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), pharmacokinetic parameters, and anti-tumor activity of MK-0731, a potent inhibitor of KSP. " 06/01/2012
- " MK-0731 at the MTD of 17 mg/m(2)/day every 21 days in patients with solid tumors had few grade 3 and 4 toxicities with the major DLTs at higher doses being myelosuppression. " 06/01/2012
- " In part 1, patients with advanced solid tumors received MK-0731 intravenously over 24 h every 21 days starting at 6 mg/m(2), escalating until MTD was reached. " 06/01/2012
- " A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors." 11/01/2010
- " Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs."
|
|
Related Drugs and Biologics